387 results on '"Maraskovsky, Eugene"'
Search Results
2. Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer
3. Recombinant NY-ESO-1 Protein with ISCOMATRIX Adjuvant Induces Broad Integrated Antibody and CD4+ and CD8+ T Cell Responses in Humans
4. Immunodominant CD4 + Responses Identified in a Patient Vaccinated with Full-Length NY-ESO-1 Formulated with ISCOMATRIX Adjuvant
5. Data from Optimal Effector Functions in Human Natural Killer Cells Rely upon Autocrine Bone Morphogenetic Protein Signaling
6. Data Supplement from Optimal Effector Functions in Human Natural Killer Cells Rely upon Autocrine Bone Morphogenetic Protein Signaling
7. G-CSF and Neutrophils Are Nonredundant Mediators of Murine Experimental Autoimmune Uveoretinitis
8. Role of viral RNA and lipid in the adverse events associated with the 2010 Southern Hemisphere trivalent influenza vaccine
9. Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere Trivalent Influenza Vaccine is associated with adverse events
10. Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma
11. Lymphoid Development and Function in IL-7R-Deficient Mice
12. Dramatic Numerical Increase of Functionally Mature Dendritic Cells in FLT3 Ligand-Treated Mice
13. The Dominant Role of CD8⁺ Dendritic Cells in Cross-Presentation Is Not Dictated by Antigen Capture
14. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery
15. Presentation of tumour antigens by dendritic cells and challenges faced
16. Activin-A attenuates several human natural killer cell functions
17. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement
18. Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™
19. P2Y receptor signaling regulates phenotype and IFN-α secretion of human plasmacytoid dendritic cells
20. Activin-A: a novel dendritic cell–derived cytokine that potently attenuates CD40 ligand–specific cytokine and chemokine production
21. N-Linked Glycans on Therapeutic Factor VIII (FVIII) Proteins Attenuate Immunogenicity Potential: Evidence from Independent HLA-Class-II/FVIII (HLAcII/FVIII) Peptidomes
22. Disentangling the Effects of HLA DRB1*15:01 and DQB1*06:02 to Establish the True HLA Risk Allele for Inhibitor Development in the Treatment of Hemophilia A
23. Immunodominant CD[4.sup.+] responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant
24. Combination of adjuvants: the future of vaccine design
25. Adaptive functional differentiation of dendritic cells: integrating the network of extra- and intracellular signals
26. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases
27. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway
28. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma†
29. Butyrophilin molecules govern γδ T cell reactivity against phosphoantigens
30. Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma
31. Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells
32. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant
33. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIXTM vaccine; A phase I study in healthy volunteers
34. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery
35. Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway
36. Dendritic cell development
37. Cancer vaccines for established cancer: how to make them better?
38. Normal proportion and expression of maturation markers in migratory dendritic cells in the absence of germs or Toll-like receptor signaling
39. ISCOMATRIX™ adjuvant for prophylactic and therapeutic vaccines
40. Directions in the immune targeting of cancer: Lessons learned from the cancer-testis Ag NY-ESO-1
41. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
42. Bcl-2 can rescue T lymphocyte dvelopment in interleukin-7 receptor-deficient mice but not in mutant rag-1(super -l-) mice
43. NK cells
44. Dendritic cells as recipients of cytokine signals
45. Contributors
46. Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells
47. Fms-like tyrosine kinase 3 ligand administration overcomes a genetically determined dendritic cell deficiency in NOD mice and protects against diabetes development
48. Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells
49. Developmental Options
50. Physiological Regulators of the Migration and Cytokine Secretion of in vitro-derived and Blood-derived DC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.